Nanni C - Search Results

1

Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours.

Lopci E, Nanni C, Rampin L, Rubello D, Fanti S. Lopci E, et al. Among authors: nanni c. Minerva Endocrinol. 2008 Sep;33(3):277-81. Minerva Endocrinol. 2008. PMID: 18846030 Review.

2

Somatostatin receptor scintigraphy for bronchial carcinoid follow-up.

Fanti S, Farsad M, Battista G, Monetti F, Montini GC, Chiti A, Savelli G, Petrella F, Bini A, Nanni C, Romeo A, Franchi R, Bombardieri E, Canini R, Monetti N. Fanti S, et al. Among authors: nanni c. Clin Nucl Med. 2003 Jul;28(7):548-52. doi: 10.1097/00003072-200307000-00003. Clin Nucl Med. 2003. PMID: 12819406 Clinical Trial.

3

Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.

Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S. Nanni C, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):149-54. doi: 10.1089/108497804323071913. Cancer Biother Radiopharm. 2004. PMID: 15186594 Clinical Trial.

4

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients.

Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, Alinari L, Farsad M, Musuraca G, Gabriele A, Marchi E, Nanni C, Canini R, Monetti N, Baccarani M. Zinzani PL, et al. Among authors: nanni c. Br J Cancer. 2004 Aug 31;91(5):850-4. doi: 10.1038/sj.bjc.6602040. Br J Cancer. 2004. PMID: 15266320 Free PMC article.

5

Myocardial SPECT: what do we gain from attenuation correction (and when)?

Dondi M, Fagioli G, Salgarello M, Zoboli S, Nanni C, Cidda C. Dondi M, et al. Among authors: nanni c. Q J Nucl Med Mol Imaging. 2004 Sep;48(3):181-7. Q J Nucl Med Mol Imaging. 2004. PMID: 15499291 Free article. Clinical Trial.

6

18F-FDG PET early after radiotherapy in lymphoma patients.

Castellucci P, Zinzani P, Nanni C, Farsad M, Moretti A, Alinari L, Battista G, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Fanti S. Castellucci P, et al. Among authors: nanni c. Cancer Biother Radiopharm. 2004 Oct;19(5):606-12. doi: 10.1089/cbr.2004.19.606. Cancer Biother Radiopharm. 2004. PMID: 15650453

7

Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients.

Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, Barile C, Rampin L, Nibale O, Fanti S. Nanni C, et al. Eur J Nucl Med Mol Imaging. 2005 May;32(5):589-92. doi: 10.1007/s00259-004-1734-3. Epub 2005 Feb 22. Eur J Nucl Med Mol Imaging. 2005. PMID: 15726356 Clinical Trial.

8

18F-FDG PET in malignant lymphoma: significance of positive findings.

Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S. Castellucci P, et al. Among authors: nanni c. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):749-56. doi: 10.1007/s00259-004-1748-x. Epub 2005 Mar 23. Eur J Nucl Med Mol Imaging. 2005. PMID: 15785956

9

(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.

Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P, Rampin L, Mariani G, Fanti S. Nanni C, et al. Eur J Surg Oncol. 2005 Sep;31(7):792-7. doi: 10.1016/j.ejso.2005.02.029. Eur J Surg Oncol. 2005. PMID: 15893908 Clinical Trial.

10

Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.

Castellucci P, Nanni C, Farsad M, Alinari L, Zinzani P, Stefoni V, Battista G, Valentini D, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Franchi R, Rampin L, Fanti S, Rubello D. Castellucci P, et al. Among authors: nanni c. Nucl Med Commun. 2005 Aug;26(8):689-94. doi: 10.1097/01.mnm.0000171781.11027.bb. Nucl Med Commun. 2005. PMID: 16000986

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results